Danelle Johnston, Cheryl Bellomo, and Wendy Latash discuss how the AONN+ Acuity Tool stemmed from a need for a validated, standardized tool that can measure the intensity of the work of both clinical and nonclinical navigators.
Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.
Prostate cancer is the most common male malignancy. In 2021, the United States will see an estimated 248,530 new cases, 34,130 deaths, and more than 3 million survivors.